Life Sciences Stocks
Entities in this sector focus on the research, development, and commercialization of therapeutic modalities, synthetic biology tools, and diagnostic platforms aimed at treating complex human diseases and improving agricultural yields. Revenue models transition from intensive research and development phases toward milestone-based licensing, royalty streams, or direct commercial product sales.
As of Oct 23, 2026, Life Sciences has 568 US-listed companies worth $4T combined. The median member moved +1.7% over the past week; BIIB led among the 25 largest at +7.8% and MRNA trailed at -8.2%.
Companies in Life Sciences
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- TMO – Thermo Fisher Scientific Inc, $249B
- AMGN – Amgen Inc, $237B
- GILD – Gilead Sciences Inc, $193B
- ABT – Abbott Laboratories, $177B
- PFE – Pfizer Inc, $171B
- DHR – Danaher Corporation, $162B
- VRTX – Vertex Pharmaceuticals Inc, $136B
- GSK – GlaxoSmithKline PLC ADR, $103B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- MRNA – Moderna Inc, $79.9B
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- NTRA – Natera Inc, $57.9B
- ARGX – argenx NV ADR, $54.9B
- BDX – Becton Dickinson and Company, $54.6B
- VEEV – Veeva Systems Inc Class A, $52.2B
- EW – Edwards Lifesciences Corp, $51.9B
- A – Agilent Technologies Inc, $48.8B
- IQV – IQVIA Holdings Inc, $45.8B
- WAT – Waters Corporation, $44.9B
- ILMN – Illumina Inc, $40.7B
- RVMD – Revolution Medicines Inc, $40.2B
- BIIB – Biogen Inc, $37B
- RPRX – Royalty Pharma Plc, $36.8B
- ZTS – Zoetis Inc, $33.9B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- DXCM – DexCom Inc, $29.6B
- IR – Ingersoll Rand Inc, $28.8B
- WST – West Pharmaceutical Services Inc, $27.7B
- ROIV – Roivant Sciences Ltd, $27.1B
- GMAB – Genmab AS, $26.9B
- DGX – Quest Diagnostics Incorporated, $26.9B
- LH – Laboratory Corporation of America Holdings, $26.7B
- UTHR – United Therapeutics Corporation, $25.1B
- IFF – International Flavors & Fragrances Inc, $23.9B
- INCY – Incyte Corporation, $23.7B
- BNTX – BioNTech SE, $22.9B
- STE – STERIS plc, $22.6B
- GH – Guardant Health Inc, $21.9B
- INSM – Insmed Inc, $20.4B
- MEDP – Medpace Holdings Inc, $18.3B
- RVTY – Revvity Inc., $17.7B
- CRL – Charles River Laboratories, $16.6B
- EXEL – Exelixis Inc, $16.2B
- ASND – Ascendis Pharma AS, $16B
- ICLR – ICON PLC, $14.3B
- HALO – Halozyme Therapeutics Inc, $14.1B
- BBIO – BridgeBio Pharma Inc, $13.4B
- DOC – Healthpeak Properties Inc, $13.1B
- TEM – Tempus AI, Inc. Class A Common Stock, $12.3B
- AVTR – Avantor Inc, $11.7B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- TECH – Bio-Techne Corp, $11.4B
- RGEN – Repligen Corporation, $11.3B
- ELAN – Elanco Animal Health, $11.3B
- RDY – Dr. Reddy’s Laboratories Ltd ADR, $11B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- QGEN – Qiagen NV, $10.4B
- PCVX – Vaxcyte Inc, $9.9B
- TWST – Twist Bioscience Corp, $9.9B
- TXG – 10X Genomics Inc, $9.8B
- BIO – Bio-Rad Laboratories Inc, $9.6B
- KRYS – Krystal Biotech Inc, $9.6B
- KYMR – Kymera Therapeutics Inc, $9.3B
- CAI – Caris Life Sciences, Inc. Common Stock, $9B
- IBRX – Immunitybio Inc, $8.8B
- BRKR – Bruker Corporation, $8.7B
- SYRE – Spyre Therapeutics Inc., $8.7B
- CYTK – Cytokinetics Inc, $8.5B
- CTVA – Corteva Inc, $8.5B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- ARE – Alexandria Real Estate Equities Inc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- LNTH – Lantheus Holdings Inc, $6.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- BLCO – Bausch + Lomb Corp, $6.2B
- LGND – Ligand Pharmaceuticals Incorporated, $6.1B
- IMVT – Immunovant Inc, $5.9B
- BLTE – Belite Bio Inc ADR, $5.8B
- GRAL – GRAIL, LLC, $5.7B
- STVN – Stevanato Group SpA, $5.5B
- COGT – Cogent Biosciences Inc, $5.5B
- KOD – Kodiak Sciences Inc, $5.4B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- GRFS – Grifols SA ADR, $5.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- ERAS – Erasca Inc, $5.1B
- TVTX – Travere Therapeutics Inc, $4.9B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- CRSP – Crispr Therapeutics AG, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- KRC – Kilroy Realty Corp, $4.4B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- RLAY – Relay Therapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- ABCL – Abcellera Biologics Inc, $3.8B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- VCYT – Veracyte Inc, $3.7B
- EXPO – Exponent Inc, $3.7B
- CDNA – CareDx Inc, $3.6B
- LQDA – Liquidia Technologies Inc, $3.6B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- IDYA – Ideaya Biosciences Inc, $3.5B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- VKTX – Viking Therapeutics Inc, $3.3B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- HTGC – Hercules Capital, Inc., $3.1B
- IRON – Disc Medicine Inc., $3B
- DNLI – Denali Therapeutics Inc, $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- ELVN – Enliven Therapeutics Inc., $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- VRDN – Viridian Therapeutics Inc, $2.5B
- BEAM – Beam Therapeutics Inc, $2.5B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- HCM – HUTCHMED DRC, $2.5B
- MRVI – Maravai Lifesciences Holdings Inc, $2.4B
- ADMA – ADMA Biologics Inc, $2.4B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- CLDX – Celldex Therapeutics Inc, $2.3B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PGEN – Precigen Inc, $2.3B
- AGIO – Agios Pharm, $2.2B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- AXGN – Axogen Inc, $2.2B
- FTRE – Fortrea Holdings Inc., $2.1B
- VCEL – Vericel Corp Ord, $2.1B
- PHVS – Pharvaris BV, $2.1B
- IMNM – Immunome Inc, $2.1B
- WGS – GeneDx Holdings Corp., $2B
- XERS – Xeris Pharmaceuticals Inc, $2B
- BCRX – BioCryst Pharmaceuticals Inc, $2B
- ALMR – Alamar Biosciences, Inc. Common Stock, $2B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- RXRX – Recursion Pharmaceuticals Inc, $1.9B
- DHC – Diversified Healthcare Trust, $1.9B
- BLFS – BioLife Solutions Inc, $1.9B
- NVAX – Novavax Inc, $1.9B
- XNCR – Xencor Inc, $1.9B
- SEPN – Septerna, Inc. Common Stock, $1.8B
- VIR – Vir Biotechnology Inc, $1.8B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- NVCR – Novocure Ltd, $1.8B
- PVLA – Palvella Therapeutics, Inc, $1.7B
- SDGR – Schrodinger Inc, $1.7B
- NUVB – Nuvation Bio Inc, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- ANIP – ANI Pharmaceuticals Inc, $1.7B
- NBTX – Nanobiotix, $1.7B
- OCUL – Ocular Therapeutix Inc, $1.7B
- STOK – Stoke Therapeutics Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- NTLA – Intellia Therapeutics Inc, $1.6B
- QURE – Uniqure NV, $1.6B
- CMPS – Compass Pathways Plc, $1.6B
- RARE – Ultragenyx, $1.6B
- IMCR – Immunocore Holdings Ltd, $1.5B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- AZTA – Azenta Inc, $1.5B
- ABSI – Absci Corp, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- TSHA – Taysha Gene Therapies Inc, $1.4B
- IIPR – Innovative Industrial Properties Inc, $1.4B
- DRTS – Alpha Tau Medical Ltd, $1.3B
- REPL – Replimune Group Inc, $1.3B
- MNKD – MannKind Corp, $1.2B
- NKTR – Nektar Therapeutics, $1.2B
- VOR – Vor Biopharma Inc, $1.2B
- OMER – Omeros Corporation, $1.2B
- OPK – Opko Health Inc, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- HROW – Harrow Health Inc, $1.1B
- TNDM – Tandem Diabetes Care Inc, $1.1B
- JANX – Janux Therapeutics Inc, $1.1B
- CSTL – Castle Biosciences Inc, $1.1B
- IMTX – Immatics NV, $1B
- SVRA – Savara Inc, $1B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- CGEM – Cullinan Oncology LLC, $961M
- MGTX – MeiraGTx Holdings PLC, $955M
- CLVT – CLARIVATE PLC, $947M
- KURA – Kura Oncology Inc, $944M
- BVS – Bioventus Inc, $897M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- ALMS – Alumis Inc, $885M
- QDEL – Quidel Corporation, $885M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- CYRX – Cryoport Inc, $879M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SANA – Sana Biotechnology Inc, $835M
- IMMX – Immix Biopharma Inc, $803M
- HELP – Cybin Inc., $799M
Showing the 200 largest of 568 members by market cap.